Sipuleucel-t is an autologous immunotherapy that activates a man’s immune cells to multiply and attack prostate cancer cells by way of activating certain immune cells with a vaccine that triggers immune cells to identify prostate cancer cells by an antigen that is highly specific to prostate cancer.
Is sipuleucel-T a passive immunotherapy agent?
Sipuleucel-T is an active cellular immunotherapy for asymptomatic or minimally symptomatic mCRPC.
What is Provenge treatment for cancer?
PROVENGE (sipuleucel-T) is an autologous cellular immunotherapy designed to stimulate a patient’s own immune system against cancer. PROVENGE is manufactured in several steps. First the patient’s blood is run through a machine in a process known as leukapheresis.
What is an example of a passive immunotherapy agent?
Passive Immunotherapy Specific treatments include monoclonal antibodies (MABs), the so-called magic bullets, which can be designed to target certain cancer cells.
What is sipuleucel-T used for?
A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels).
How effective is sipuleucel?
With a median follow-up of 34.1 months and complete survival follow-up data for 99% of patients, treatment with sipuleucel-T resulted in a 4.1-month improvement in median survival and an improvement in the rate of 3-year survival (31.7% for patients receiving sipuleucel-T, as compared with 23.0% for those receiving …
What is passive immunotherapy?
A type of immunotherapy in which donated or laboratory-made immune system components or cellular proteins are given to a person to help the person fight an infection or disease. Passive immunotherapy using antibodies is often used in cancer treatment.
How does sipuleucel-T PROVENGE work?
Sipuleucel-T, an autologous cellular immunological agent, is thought to work through APCs to stimulate T-cell immune response targeted against prostatic acid phosphatase (PAP), an antigen that is highly expressed in most prostate cancer cells.
What is the difference between active immunization and passive immunotherapy?
Active immunotherapies induce an immune response through direct immune system stimulation, while immunotherapies that administer antibodies directly to the system are classified as passive immunotherapies.
What is passive antibody treatment?
Passive immunization with convalescent plasma involves transfusing the acellular portion of blood from individuals who have recovered from an infection to persons who are infected or at risk of infection. Plasma donors are presumed to have developed an effective antibody response to the offending pathogen.
Does sipuleucel-t work?
In late-stage, randomized trials, this drug showed a statistically significant extended survival of at least 4.1 months and an overall survival of about 20 months, when compared with placebo. Men receiving sipuleucel-T experienced a 22.5% overall reduced risk of death compared with the control group.
Is Sipuleucel-T an immunostimulant?
While referred to as a therapeutic vaccine rather than a preventive vaccine that prevents infectious disease, sipuleucel-T is instead an immunostimulant. On February 20, 2015, Valeant Pharmaceuticals received approval to purchase all Dendreon assets (including Provenge).
What is Sipuleucel-T made of?
Sipuleucel-T is composed of recombinant antigen protein, which must be incubated with the patient’s isolated APCs ex vivo. The procedure starts at the physician’s office, the blood-collection center, or the laboratory, where blood containing the APCs is collected by leukapheresis.
Does Sipuleucel-T work through APCs?
Sipuleucel-T, an autologous cellular immunological agent, is thought to work through APCs to stimulate T-cell immune response targeted against prostatic acid phosphatase (PAP), an antigen that is highly expressed in most prostate cancer cells.6,10,15,17
What is the dose of sipuleucel?
DOSAGE AND ADMINISTRATION. The sipuleucel-T dose is a minimum of 50 million autologous CD54+ cells activated with PAP or GM–CSF, suspended in 250 mL of lactated Ringer’s solution USP, in a sealed infusion bag designated for each patient. The vaccine is given every two weeks for 60 minutes in three doses.
